文献速递类风湿关节炎

钙卫蛋白作为早期类风湿关节炎炎症标志物的研究

Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2017-08-16

该研究纳入215例病程小于2年的未使用改善病情抗风湿药的早期类风湿关节炎患者,在基线和治疗1、3、12个月检测血浆钙卫蛋白。结果显示钙卫蛋白与治疗前疾病活动度、血沉和超声能量多普勒相关,治疗12个月后仍与能量多普勒相关,且基线高水平钙卫蛋白与影像学进展相关,但不能预测治疗反应。

要点

  • 钙卫蛋白与早期类风湿关节炎治疗前疾病活动度、血沉及超声能量多普勒显著相关。
  • 治疗12个月后钙卫蛋白仍与能量多普勒相关,而血沉和C反应蛋白无此相关性。
  • 基线钙卫蛋白、血沉和C反应蛋白均不能预测治疗反应,但高钙卫蛋白与影像学进展相关。

核心结论

  • 钙卫蛋白与超声评估的炎症相关,且与影像学进展相关,可能作为评估类风湿关节炎不同阶段疾病活动度的炎症标志物。

研究设计与样本

  • 研究纳入215例符合2010年美国风湿病学会/欧洲抗风湿病联盟分类标准、病程小于2年、未使用改善病情抗风湿药的类风湿关节炎患者,所有患者接受达标治疗,为随机对照策略试验(ARCTIC)的一部分。

主要发现

  • 治疗前钙卫蛋白与临床疾病活动指数(r=0.32)、血沉(r=0.50)和超声能量多普勒(r=0.42)显著相关。
  • 治疗12个月后,钙卫蛋白与能量多普勒显著相关(r=0.27),而血沉和C反应蛋白与能量多普勒无显著相关。
  • 基线钙卫蛋白、血沉和C反应蛋白均不能预测治疗反应。
  • 多变量模型中,基线高水平的钙卫蛋白与影像学进展相关。

临床怎么用

  • 钙卫蛋白可作为评估早期类风湿关节炎疾病活动度的炎症标志物,尤其在超声评估炎症方面具有潜在价值。
  • 基线钙卫蛋白水平可能有助于识别影像学进展风险较高的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Calprotectin is an inflammatory marker of interest in rheumatoid arthritis (RA). We evaluated whether the level of calprotectin was associated with disease activity, and if it was predictive of treatment response and radiographic progression in patients with early RA. METHODS: Plasma from disease-modifying antirheumatic drug (DMARD)-naïve patients with RA fulfilling 2010 American College of Rheumatology/European League Against Rheumatism classification criteria with symptom duration <2 years was analysed for calprotectin at baseline, and after 1, 3 and 12 months. All patients received treat-to-target therapy, as part of a randomised controlled strategy trial (ARCTIC). The association between calprotectin, erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) and measures of disease activity were assessed by correlations. We used likelihood ratios and logistic regression models to assess the predictive value of the baseline inflammatory markers for treatment response and radiographic damage. RESULTS: 215 patients were included: 61% female, 82% anti-citrullinated peptide antibody positive, mean (SD) age 50.9 (13.7) years and median (25, 75 percentile) symptom duration 5.8 (2.8, 10.5) months. Calprotectin was significantly correlated with Clinical Disease Activity Index (r=0.32), ESR (r=0.50) and ultrasonography power Doppler (r=0.42) before treatment onset. After 12 months of treatment, calprotectin, but not ESR and CRP, was significantly correlated with power Doppler (r=0.27). Baseline levels of calprotectin, ESR and CRP were not predictive of treatment response, but high levels of calprotectin were associated with radiographic progression in multivariate models. CONCLUSIONS: Calprotectin was correlated with inflammation assessed by ultrasound before and during DMARD treatment, and was also associated with radiographic progression. The data support that calprotectin may be of interest as an inflammatory marker when assessing disease activity in different stages of RA. TRIAL REGISTRATION NUMBER: NCT01205854; Post-results.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Jonsson MK, Sundlisæter NP, Nordal HH, et al. Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis. Ann Rheum Dis. 2017. PMID: 28814431. doi:10.1136/annrheumdis-2017-211695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。